
Serostim Enhances Bone Density, Reduces Fractures in American Males with Osteoarthritis
Reading Time: 2 minutes Introduction Osteoarthritis (OA) is a prevalent degenerative joint disease that significantly affects the quality of life of millions of American males. As the population ages, the incidence of OA and its associated complications, such as decreased bone density and increased fracture risk, continue to rise. Serostim, a recombinant human growth hormone, has been proposed as a potential therapeutic agent for managing OA due to its anabolic effects on bone tissue. This article presents a comprehensive analysis of the influence of Serostim on bone health in American males with osteoarthritis over a three-year period, focusing on bone density and fracture rates....